Jelovsek F R, Hammond C B, Woodard B H, Draffin R, Lee K L, Creasman W T, Parker R T
Am J Obstet Gynecol. 1980 May 1;137(1):85-91. doi: 10.1016/0002-9378(80)90390-7.
A retrospective study was carried out on 431 patients with endometrial cancer and 431 control subjects matched as to age, race, and parity. They were seen at Duke University Medical Center from 1940 to 1975. The study was performed in order to evaluate the risk of exogenous estrogen therapy and the development of adenocarcinoma of the endometrium. The overall risk was 2.38, with certain subgroups demonstrating different degrees of risk. Increased risk was associated with estrogen therapy of longer than 5 years' duration in white patients. The risk also was confined to Stage I, grade 1 lesions and more superficial myometrial invasion. Five-year survival for patients who used estrogen replacement and had Stage I, grade 1 lesions was 94.7%. The risks associated with exogenous estrogens are real but should be considered in a risk/benefit context when prescribing for the needs of an individual patient.
对431例子宫内膜癌患者和431例年龄、种族及产次相匹配的对照者进行了一项回顾性研究。他们于1940年至1975年在杜克大学医学中心接受诊治。开展该研究是为了评估外源性雌激素治疗的风险以及子宫内膜腺癌的发生情况。总体风险为2.38，某些亚组显示出不同程度的风险。白人患者中，使用雌激素治疗超过5年与风险增加相关。该风险也仅限于Ⅰ期、1级病变以及肌层浸润较浅的情况。使用雌激素替代疗法且患有Ⅰ期、1级病变的患者5年生存率为94.7%。外源性雌激素相关的风险是真实存在的，但在为个体患者的需求开药时，应在风险/获益的背景下予以考虑。
